Discussion
An investigational off-the-shelf, or readily available, CAR T-cell therapy has shown early signs of effectiveness — with clinical improvements and no serious safety concerns — in the first four people with systemic sclerosis (SSc) treated in an ongoing clinical trial in the U.S. and Europe. That’s according to preliminary…